Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOPAR vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Acne vulgaris,Brucellosis,Cholera,Granuloma inguinale,Listeriosis,Lymphogranuloma venereum,Mycoplasma pneumoniae infection,Psittacosis,Q fever,Rocky Mountain spotted fever,Syphilis (when penicillin contraindicated),Trachoma,Tularemia,Urinary tract infections (caused by susceptible organisms)
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
500 mg orally twice daily for 7-14 days.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Tetracycline is not extensively metabolized; primarily excreted unchanged in urine and feces.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal (80-90% unchanged), fecal (10-20%)
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
25-30% bound to albumin
30-35% bound to albumin.
0.2-0.3 L/kg (suggests low tissue penetration; primarily extracellular fluid)
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 60-75%; IM: ~100%
Oral: 70-85% with high variability; intrathecal: 100%.
Cr Cl 30-50 m L/min: 500 mg once daily; Cr Cl 15-29 m L/min: 250 mg once daily; Cr Cl <15 m L/min or on dialysis: 250 mg every 48 hours.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
No adjustment required for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): use with caution; consider reduced dose.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
For children >1 year: 15 mg/kg/day divided every 12 hours, not to exceed 500 mg per dose.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
No specific dose adjustment based on age alone; dose based on renal function. Use minimum effective dose and monitor renal function.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Tetracycline use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Photosensitivity: exaggerated sunburn reaction may occur.,Hepatotoxicity: rare but can occur, especially in patients with renal impairment.,Renal impairment: may require dose adjustment; avoid in severe renal dysfunction.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea may occur.,Superinfection: overgrowth of nonsusceptible organisms including fungi.,Use in pregnancy: category D; avoid due to risk to fetus.,Use in children <8 years: avoid due to tooth discoloration and bone growth inhibition.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to tetracycline or any component,Pregnancy (last half),Children under 8 years,Severe hepatic or renal impairment
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum within 2 hours of taking cyclopar. Iron supplements, zinc, and bismuth subsalicylate also reduce absorption. Take with a full glass of water; avoid concurrent intake of high-iron foods (e.g., spinach, red meat) within 1-2 hours. No significant interaction with alcohol but caution due to potential hepatotoxicity.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, tetracyclines can cause reversible inhibition of fetal bone growth. Avoid during pregnancy; alternative antibiotics should be selected.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Tetracyclines are excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.5. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. However, due to poor oral absorption and binding to milk calcium, systemic exposure is minimal. Use is generally considered compatible with breastfeeding if short-term; caution is advised with prolonged therapy.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No pharmacokinetic data specifically for pregnancy; standard adult dosing may be used if absolutely necessary, but use is discouraged. If unavoidable, monitor serum levels (therapeutic range 5–10 mcg/m L) as pregnancy-induced changes in volume of distribution and renal clearance may alter drug exposure. Dose adjustments should be guided by clinical response and serum levels.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Cyclopar (tetracycline) should be taken on an empty stomach 1 hour before or 2 hours after meals to enhance absorption. Avoid concurrent use with dairy products, antacids, or iron supplements due to chelation. Photosensitivity is common; advise sun protection. Monitor for superinfection, especially C. difficile colitis. Use with caution in renal impairment; adjust dose to avoid nephrotoxicity. Not recommended in children under 8 years or during pregnancy due to bone and teeth discoloration.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take this medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium-rich foods for at least 2 hours before and after taking this drug.,This drug can make your skin more sensitive to sunlight; use sunscreen, wear protective clothing, and avoid tanning beds.,Complete the full course of treatment even if you feel better; do not skip doses.,Inform your doctor if you experience severe diarrhea, vaginal itching, or oral thrush as these may indicate a secondary infection.,Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor.,Store at room temperature away from moisture and heat. Do not use outdated tetracycline as it can become toxic.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOPAR vs BACLOFEN, answered by our medical review team.
CYCLOPAR is a Muscle Relaxant that works by Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOPAR and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOPAR is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOPAR and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOPAR is classified as Category C. Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gr. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.